Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
March 19, 2007
- MEDICAL DEVICE NEWS IN BRIEF
March 19, 2007
- 7 APIs Including Celecoxib to Be Included in NHI Price List
March 19, 2007
- Efficacy of Narcotic Analgesics Predicted by Gene Polymorphisms
March 19, 2007
- Gov't-Private Sector Dialogueto Be Held on Distribution
March 19, 2007
- Consider Licensing, Not Independent Marketing, in Advanced Countries: Mr Seko
March 19, 2007
- Warning against Exacerbation of Hepatitis Added to Package Insert of Rituximab
March 19, 2007
- Amended PAL Presents Opportunities: JACDS
March 19, 2007
- REGULATORY NEWS IN BRIEF
March 19, 2007
- 6-Year Education Makes Schools of Pharmacy Less Attractive: Survey
March 19, 2007
- PMDA to Hire 236 New Reviewers by End of FY2009
March 19, 2007
- Global Sales of 3 New Strategic Products to Exceed US$1.5 Bil. Each: Mr Naito
March 19, 2007
- Lactoferrin Improves Dyslipidemia: Lion
March 19, 2007
- Seretide Reduces Risk of Death in COPD: GSK
March 19, 2007
- Japan, China Agree to Cooperate in Developing Anticancer Drugs
March 19, 2007
- SymBio Completes Enrollment into PI Trial of Bendamustine
March 19, 2007
- Preminent Maintains Top Position: Rep Track Survey
March 12, 2007
- Pfizer Japan Needs Flat, Agile Organization: Mr Iwasaki
March 12, 2007
- DSM to Expand Its Business in Life Sciences
March 12, 2007
- BUSINESS NEWS IN BRIEF
March 12, 2007
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…